Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 50% ± 6% |
Insufficient scRNA-seq data for expression of CYP2W1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 2164.42 | 258 / 258 | 38% | 9.74 | 87 / 230 |
intestine | 30% | 56.26 | 289 / 966 | 77% | 61.00 | 407 / 527 |
ovary | 71% | 160.67 | 127 / 180 | 20% | 3.13 | 86 / 430 |
prostate | 70% | 259.11 | 172 / 245 | 19% | 0.82 | 94 / 502 |
bladder | 33% | 77.24 | 7 / 21 | 43% | 21.80 | 216 / 504 |
stomach | 6% | 6.80 | 22 / 359 | 69% | 75.75 | 198 / 286 |
skin | 71% | 738.11 | 1285 / 1809 | 1% | 0.19 | 5 / 472 |
esophagus | 17% | 23.65 | 243 / 1445 | 55% | 30.99 | 101 / 183 |
pancreas | 8% | 6.55 | 25 / 328 | 49% | 10.06 | 88 / 178 |
uterus | 2% | 3.28 | 4 / 170 | 37% | 8.70 | 168 / 459 |
spleen | 34% | 34.02 | 81 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 31% | 1.95 | 14 / 45 |
lung | 2% | 2.84 | 14 / 578 | 25% | 9.60 | 293 / 1155 |
thymus | 0% | 0.10 | 1 / 653 | 20% | 5.88 | 119 / 605 |
liver | 0% | 0.31 | 1 / 226 | 8% | 0.52 | 33 / 406 |
kidney | 4% | 3.01 | 4 / 89 | 2% | 0.26 | 19 / 901 |
breast | 1% | 0.94 | 4 / 459 | 1% | 0.15 | 16 / 1118 |
adipose | 1% | 2.18 | 17 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.03 | 1 / 80 |
blood vessel | 1% | 1.04 | 7 / 1335 | 0% | 0 | 0 / 0 |
brain | 0% | 0.39 | 6 / 2642 | 0% | 0.01 | 1 / 705 |
peripheral blood | 0% | 0.08 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006805 | Biological process | xenobiotic metabolic process |
GO_1903604 | Biological process | cytochrome metabolic process |
GO_0046222 | Biological process | aflatoxin metabolic process |
GO_0006082 | Biological process | organic acid metabolic process |
GO_0006644 | Biological process | phospholipid metabolic process |
GO_0034653 | Biological process | retinoic acid catabolic process |
GO_0005886 | Cellular component | plasma membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0009986 | Cellular component | cell surface |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0005737 | Cellular component | cytoplasm |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0016712 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen |
GO_0004497 | Molecular function | monooxygenase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0008401 | Molecular function | retinoic acid 4-hydroxylase activity |
GO_0020037 | Molecular function | heme binding |
GO_0001972 | Molecular function | retinoic acid binding |
GO_0005503 | Molecular function | all-trans retinal binding |
GO_1904768 | Molecular function | all-trans-retinol binding |
Gene name | CYP2W1 |
Protein name | Cytochrome P450 family 2 subfamily W member 1 Cytochrome P450 2W1 (EC 1.14.14.-) (CYPIIW1) |
Synonyms | |
Description | FUNCTION: A cytochrome P450 monooxygenase that may play a role in retinoid and phospholipid metabolism . Catalyzes the hydroxylation of saturated carbon hydrogen bonds. Hydroxylates all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may regulate atRA clearance. Other retinoids such as all-trans retinol and all-trans retinal are potential endogenous substrates . Catalyzes both epoxidation of double bonds and hydroxylation of carbon hydrogen bonds of the fatty acyl chain of 1-acylphospholipids/2-lysophospholipids. Can metabolize various lysophospholipids classes including lysophosphatidylcholines (LPCs), lysophosphatidylinositols (LPIs), lysophosphatidylserines (LPSs), lysophosphatidylglycerols (LPGs), lysophosphatidylethanolamines (LPEs) and lysophosphatidic acids (LPAs) . Has low or no activity toward 2-acylphospholipids/1-lysophospholipids, diacylphospholipids and free fatty acids . May play a role in tumorigenesis by activating procarcinogens such as aflatoxin B1, polycyclic aromatic hydrocarbon dihydrodiols and aromatic amines . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) . . |
Accessions | H7C015 ENST00000415893.1 ENST00000340150.10 A6NJ10 ENST00000308919.12 Q8TAV3 |